Diabetes News and Research

Latest Diabetes News and Research

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

1 Jul 2010

Roche, IBM announce agreement to develop nanopore-based sequencer for decoding human DNA

Roche and IBM announced today an agreement to develop a nanopore-based sequencer that will directly read and decode human DNA quickly and efficiently. Focused on advancing IBM's recently published "DNA Transistor" technology, the collaboration will take advantage of IBM's leadership in microelectronics, information technology and computational biology and Roche's expertise in medical diagnostics and genome sequencing.

1 Jul 2010

Prasco commences shipments of generic prescription ZEGERID Capsules

Santarus, Inc., a specialty biopharmaceutical company, today announced that pursuant to its distribution and supply agreement with Prasco, LLC, Prasco is commencing shipments of an authorized generic of prescription ZEGERID® (omeprazole/ sodium bicarbonate) Capsules in 20 mg and 40 mg dosage strengths in the U.S. under the Prasco label. ZEGERID is an immediate-release proton pump inhibitor (PPI) approved as a prescription product in the U.S. for the treatment of certain upper gastrointestinal diseases and disorders.

1 Jul 2010

GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market

Gold Standard Diagnostics, Inc. a leading supplier of products and services to the medical diagnostic industry today announced the execution of an agreement with Axis-Shield to distribute their proprietary assays in the U.S. Market. Axis-Shield owns a number of patents in the areas of cardiovascular and neurodegenerative diseases, rheumatoid arthritis, diabetes and more recently, sepsis. GSD will initially focus on distribution of Homocysteine, but also gains access to distribute Axis-Shield's other key products such as Anti-CCP.

1 Jul 2010

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Fero Industries, Inc. is pleased to announce that it has closed the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

1 Jul 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Blue Shield of California is now offering the Healthways SilverSneakers® Fitness Program to subscribers of Blue Shield Medicare Supplement Plans throughout California. SilverSneakers, the nation's leading social support and exercise program designed to keep seniors healthy, has been a popular benefit with California Medicare HMOs, but Blue Shield is one of the few health plans in the state to offer the benefit as part of its Medicare Supplement plans as well.

30 Jun 2010

Excellence in Paediatrics to be held in London, from 2 - 4 December 2010

Experts from all over the world will be converging on the Park Plaza Hotel in Westminster, London, from 2 - 4 December 2010 for Excellence in Paediatrics, which promises cutting edge topics by outstanding speakers.

30 Jun 2010

Sensor integrated insulin pump for better blood sugar control

Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published on-line today in the New England Journal of Medicine.

30 Jun 2010

Medtronic's sensor-augmented insulin pump therapy provides superior glucose control, confirms STAR 3 study

In the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes, adult and pediatric patients using the Medtronic MiniMed Paradigm® REAL-Time System achieved better glucose control without an increase in hypoglycemia compared to multiple daily insulin injections (MDI), the most common approach to care today.

30 Jun 2010

European Congress of Nephrology unveils results of various clinical trials

The 47th ERA-EDTA/DGfN congress in Munich has been the setting for a wide range of new clinical data. The results of the following clinical trials were presented at "Late-Breaking Clinical Trials Sessions."

30 Jun 2010

Striking disparities persist; obesity rates highest among Blacks and Latinos

Adult obesity rates increased in 28 states in the past year, and declined only in the District of Columbia, according to F as in Fat: How Obesity Threatens America's Future 2010, a report from the Trust for America's Health and the Robert Wood Johnson Foundation.

30 Jun 2010

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.

30 Jun 2010

Study highlights importance of individualized, patient-centered therapies

In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.

30 Jun 2010

Physically-active women have lower risk of dementia in later life

Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.

30 Jun 2010

Metabolex, Sanofi-Aventis sign global license deal to develop GPR119 for type 2 diabetes treatment

Metabolex and Sanofi-Aventis announced today that they have entered into a global license and development agreement for the research, development, manufacture and commercialization of small molecules that modulate the G-protein coupled receptor 119 (GPR119), a receptor in the gut and pancreas that interacts with bioactive lipids to stimulate glucose-dependent incretin and insulin secretion.

30 Jun 2010

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

The Washington Post: Two new studies provide evidence "that the diabetes drug Avandia increases the risk of heart problems and strokes, renewing questions about the safety of the medication. ... The new research, released Monday, should prompt the Food and Drug Administration to remove the drug from the market, according to the researchers who led the analyses and several drug-safety advocates.

30 Jun 2010

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

30 Jun 2010

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

The U.S. Food & Drug Administration (FDA) has granted Investigational New Drug (IND) regulatory clearance to initiate a Phase I/II clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, based on research by Dr. Eli Lewis of Israel's Ben-Gurion University of the Negev.

30 Jun 2010

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

30 Jun 2010

Diabetes News and Research

Latest Diabetes News and Research

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

Roche, IBM announce agreement to develop nanopore-based sequencer for decoding human DNA

Prasco commences shipments of generic prescription ZEGERID Capsules

GSD signs agreement with Axis-Shield to distribute its proprietary assays in the U.S. Market

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Excellence in Paediatrics to be held in London, from 2 - 4 December 2010

Sensor integrated insulin pump for better blood sugar control

Medtronic's sensor-augmented insulin pump therapy provides superior glucose control, confirms STAR 3 study

European Congress of Nephrology unveils results of various clinical trials

Striking disparities persist; obesity rates highest among Blacks and Latinos

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

Study highlights importance of individualized, patient-centered therapies

Physically-active women have lower risk of dementia in later life

Metabolex, Sanofi-Aventis sign global license deal to develop GPR119 for type 2 diabetes treatment

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Diabetes News and Research

Latest Diabetes News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in